Profile data is unavailable for this security.
About the company
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
- Revenue in USD (TTM)0.00
- Net income in USD-15.68m
- Incorporated1971
- Employees20.00
- LocationVeru Inc2916 N. MIAMI AVENUE, SUITE 1000MIAMI 33127United StatesUSA
- Phone+1 (312) 595-9123
- Fax+1 (312) 595-9122
- Websitehttps://verupharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Axe Compute Inc | 728.20k | -84.01m | 34.28m | 23.00 | -- | -- | -- | 47.07 | -120.02 | -120.66 | 1.29 | -100.94 | 0.1369 | 1.34 | 2.97 | 31,660.87 | -1,579.84 | -85.09 | -- | -113.42 | 50.24 | 61.31 | -11,536.93 | -1,267.27 | 0.0134 | -0.1392 | -- | -- | -0.2384 | 2.84 | 9.63 | -- | -18.60 | -- |
| Tvardi Therapeutics Inc | 4.02m | -13.95m | 34.90m | 10.00 | -- | 1.25 | -- | 8.67 | -8.36 | -8.36 | 0.7709 | 2.97 | 0.0891 | -- | -- | 402,400.00 | -30.87 | -36.79 | -40.26 | -41.45 | 100.00 | -- | -346.55 | -155.60 | -- | -- | 0.00 | -- | -65.96 | -18.53 | 40.20 | -- | 125.35 | -- |
| Atara Biotherapeutics Inc | 151.93m | 23.40m | 35.19m | 38.00 | 2.22 | -- | 1.32 | 0.2316 | 2.19 | 2.19 | 12.81 | -5.08 | 1.76 | 3.99 | 93.55 | 993,006.60 | 27.07 | -67.79 | -- | -93.07 | 81.63 | -- | 15.40 | -558.47 | 1.02 | 15.24 | 8.31 | -- | 1,404.02 | -- | 69.07 | -- | -46.73 | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 35.60m | 4.00 | -- | -- | -- | 47,472.60 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| Actinium Pharmaceuticals Inc | 90.00k | -34.60m | 35.88m | 37.00 | -- | 2.60 | -- | 398.61 | -1.11 | -1.11 | 0.0029 | 0.4419 | 0.0013 | -- | -- | 2,432.43 | -50.05 | -43.20 | -55.95 | -47.84 | -- | -- | -38,443.33 | -7,408.74 | -- | -- | 0.0009 | -- | -100.00 | -- | 21.66 | -- | -29.66 | -- |
| Generation Bio Inc | 15.27m | -62.63m | 35.98m | 115.00 | -- | 0.7114 | -- | 2.36 | -9.35 | -9.35 | 2.28 | 7.51 | 0.0824 | -- | 11.73 | 132,782.60 | -33.79 | -35.85 | -39.21 | -38.42 | -- | -- | -410.13 | -2,304.98 | -- | -- | 0.00 | -- | 236.92 | -- | -3.99 | -- | -34.55 | -- |
| Cell Source Inc | 0.00 | -6.57m | 36.03m | -- | -- | -- | -- | -- | -0.1613 | -0.1613 | 0.00 | -0.4379 | 0.00 | -- | -- | -- | -2,039.39 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -3.74 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| Xilio Therapeutics Inc | 31.80m | -58.49m | 36.53m | 64.00 | -- | -- | -- | 1.15 | -0.6571 | -0.6571 | 0.3348 | -0.1562 | 0.3053 | -- | -- | 496,937.50 | -56.14 | -67.88 | -102.68 | -81.71 | -- | -- | -183.90 | -5,578.28 | -- | -2.84 | -- | -- | -- | -- | 23.77 | -- | -45.00 | -- |
| PDS Biotechnology Corp | 0.00 | -34.88m | 37.45m | 24.00 | -- | 3.61 | -- | -- | -0.8194 | -0.8194 | 0.00 | 0.1982 | 0.00 | -- | -- | 0.00 | -80.05 | -57.93 | -125.74 | -68.38 | -- | -- | -- | -- | -- | -8.43 | 0.6552 | -- | -- | -- | 12.42 | -- | -- | -- |
| Veru Inc | 0.00 | -15.68m | 37.56m | 20.00 | -- | 1.87 | -- | -- | -1.07 | -1.55 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -34.75 | -47.51 | -44.42 | -59.79 | -- | -- | -- | -188.81 | -- | -- | 0.00 | -- | -- | -- | 55.53 | -- | -60.02 | -- |
| Jasper Therapeutics Inc | 0.00 | -91.02m | 37.78m | 64.00 | -- | 3.26 | -- | -- | -5.90 | -5.90 | 0.00 | 0.4135 | 0.00 | -- | -- | 0.00 | -116.04 | -75.11 | -147.54 | -86.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.55 | -- | -- | -- |
| TuHURA Biosciences Inc | 0.00 | -43.77m | 38.19m | 19.00 | -- | 1.95 | -- | -- | -1.60 | -1.60 | 0.00 | 0.3273 | 0.00 | -- | -- | 0.00 | -286.97 | -- | -456.76 | -- | -- | -- | -- | -- | -- | -9.01 | 0.0286 | -- | -- | -- | -- | -- | -- | -- |
| Cypherpunk Technologies Inc | 0.00 | -50.81m | 39.32m | 52.00 | -- | 10.67 | -- | -- | -1.23 | -1.23 | 0.00 | 0.065 | 0.00 | -- | -- | 0.00 | -132.94 | -79.03 | -196.76 | -93.29 | -- | -- | -- | -9,055.53 | -- | -- | 0.00 | -- | -- | -- | 16.74 | -- | -- | -- |
| Lisata Therapeutics Inc | 1.07m | -18.24m | 40.05m | 26.00 | -- | 2.29 | -- | 37.43 | -2.13 | -2.13 | 0.1246 | 1.98 | 0.0357 | -- | -- | 41,153.85 | -60.85 | -44.77 | -71.25 | -49.07 | -- | -- | -1,704.86 | -13,065.70 | -- | -- | 0.00 | -- | -- | -- | 4.10 | -- | -- | -- |
| INmune Bio Inc | 50.00k | -49.89m | 40.14m | 22.00 | -- | 1.58 | -- | 802.87 | -2.14 | -2.14 | 0.0021 | 0.9546 | 0.0012 | -- | 0.0258 | 2,272.73 | -115.83 | -45.54 | -153.59 | -52.16 | -- | -- | -99,774.00 | -19,298.45 | -- | -942.22 | 0.00 | -- | -90.97 | -- | -40.24 | -- | -- | -- |
| Galecto Inc | 0.00 | -15.84m | 40.29m | 5.00 | -- | 5.03 | -- | -- | -12.01 | -12.01 | 0.00 | 6.03 | 0.00 | -- | -- | 0.00 | -92.89 | -47.05 | -109.09 | -50.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 44.10 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to Veru Inc's reporting currency: US Dollar USD
19.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Alyeska Investment Group LPas of 14 Jan 2026 | 1.00m | 6.23% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 547.56k | 3.41% |
| Sheets Smith Investment Management LLCas of 30 Sep 2025 | 322.08k | 2.01% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2025 | 259.54k | 1.62% |
| Millennium Management LLCas of 30 Sep 2025 | 231.60k | 1.44% |
| Oppenheimer & Co., Inc. (Wealth Management)as of 30 Sep 2025 | 192.17k | 1.20% |
| Summit Financial LLCas of 30 Sep 2025 | 163.85k | 1.02% |
| GSA Capital Partners LLPas of 30 Sep 2025 | 162.23k | 1.01% |
| Geode Capital Management LLCas of 30 Sep 2025 | 159.35k | 0.99% |
| Ikarian Capital LLCas of 30 Sep 2025 | 142.52k | 0.89% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
